Homocysteine and bone loss in epilepsy

Seizure

Volumn 16, Issue 1, 2007, Pages 22-34

  Elliott, John O ^a,b   Jacobson, Mercedes P ^a,b   Haneef, Zulfi ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AEDs; Anti epileptic drugs; Bone loss; Fractures; Homocysteine; Osteopenia; Osteoporosis

Indexed keywords

ALKALINE PHOSPHATASE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; HOMOCYSTEINE; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; PRIMIDONE; VALPROIC ACID;

ADULT; AGED; ALCOHOL CONSUMPTION; ANALYSIS OF VARIANCE; ARTICLE; BODY MASS; BODY WEIGHT; BONE DENSITY; DIET SUPPLEMENTATION; DUAL ENERGY X RAY ABSORPTIOMETRY; EPILEPSY; ETHNIC DIFFERENCE; FEMALE; FRACTURE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENOPAUSE; MONOTHERAPY; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTICONVULSANTS; BLOOD UREA NITROGEN; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM; DENSITOMETRY, X-RAY; EPILEPSY; FEMALE; FOLIC ACID; HIP; HOMOCYSTEINE; HUMANS; MALE; MIDDLE AGED; OSTEOPOROSIS; REGRESSION ANALYSIS; SPINE;

EID: 33845536803     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2006.10.001     Document Type: Article

References (62)

1. Stephen L.J., McLellan A.R., Harrison J.H., Shapiro D., Dominiczak M.H., Sills G.J., et al. Bone density and antiepileptic drugs: a case controlled study. Seizure 9 (1999) 339-342
2. U.S. Department of Health and Human Services. Bone health and osteoporosis: A report of the surgeon general. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General [online]. 2004 [cited 2005 September 8]. Available from: URL: http://www.surgeongeneral.gov/library.
3. Genant H.K., Cooper C., Poor G., Reid I., Ehrlich G., Kanis J., et al. Interim report and recommendations of the World Health Organization task-force for osteoporosis. Osteoporos Int 10 (1999) 259-264
4. Vanness D.J., and Tosteson A.N. Estimating the opportunity costs of osteoporosis in the United States. Top Geriatr Rehabil 21 (2005) 4-16
5. Fitzpatrick L.A. Secondary causes of osteoporosis. Mayo Clin Proc 77 (2002) 453-468
6. Chung S., and Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory children. Brain Dev 16 (1994) 382-385
7. Guo C.Y., Ronen G.M., and Atkinson S.A. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 42 (2001) 1141-1147
8. Gaitatzis A., Carroll K., Majeed A., and Sander J. The epidemiology of the co-morbidity of epilepsy in the general population. Epilepsia 45 (2004) 1613-1622
9. Souverein P.C., Webb D.J., Petri H., Weil J., VanStaa T.P., and Egberts T. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the general practice research database. Epilepsia 46 (2005) 304-310
10. National Institutes of Health. Osteoporosis prevention, diagnosis and therapy. NIH Consensus Statement. 2000; 17:1-52. [cited 2005 January 14]. Available from: URL: http://odp.od.nih.gov/consensus/cons/111/111_intro.htm.
11. Ensrud K.E., Walczak T.S., Blackwell T., Ensrud E.R., Bowman P.J., and Stone K.L. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 62 (2004) 2051-2057
12. Andress D.L., Ozuna J., Tirschwell D., Grande L., Johnson M., Jacobson A.F., et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 59 (2002) 781-786
13. Pack A.M., Olarte L.S., Morrell M.J., Flaster E., Resor S.R., and Shane E. Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs. Epilepsy Behav 4 (2003) 169-174
14. Sato Y., Kondo I., Ishida S., Motooka H., Takayama K., Tomita Y., et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 57 (2001) 445-449
15. Sheth R.D., Wesolowski C.A., Jacob J.C., Penney S., Hobbs G.R., Riggs J.E., et al. Effect of carbamazepine and valproate on bone mineral density. J Pediatr 127 (1995) 256-262
16. Pack A.M., Morrell M.J., Marcus R., Holloway L., Flaster E., Done S., et al. Bone mass and turnover in women with epilepsy on antiepileptic drug therapy. Ann Neurol 57 (2005) 252-257
17. Lentz S.R., and Haynes W.G. Homocysteine: is it a clinically important cardiovascular risk factor?. Cleve Clin J Med 71 (2004) 729-734
18. Apeland T., Mansoor M., and Strandjord R.E. Antiepileptic drugs as independent predictors of plasma total homocysteine levels. Epilepsy Res 47 (2001) 27-35
19. Apeland T., Mansoor M.A., Pentieva K., McNulty H., Seljeflot I., and Strandjord R.E. The effect of B-vitamins on hyperhomocysteinemia in patients on antiepileptic drugs. Epilepsy Res 51 (2002) 237-247
20. Karabiber H., Sonmezgoz E., Ozerol E., Yakinci C., Otlu B., and Yologlu S. Effects of valproate and carbamazepine on serum levels of homocysteine, Vitamin B12 and folic acid. Brain Dev 25 (2003) 113-115
21. Schwaninger M., Ringleb P., Winter R., Kohl B., Fiehn W., Reiser P.A., et al. Elevated plasma concentrations of homocysteine in antiepileptic drug treatment. Epilepsia 40 (1999) 345-350
22. Kishi T., Fujita N., Eguchi T., and Ueda K. Mechanisms for reduction of serum folate by antiepileptic drugs during prolonged therapy. J Neurol Sci 145 (1997) 109-112
23. James G.K., Jons M.W., and Pudek M.R. Homocysteine levels in patients on phenytoin therapy. Clin Biochem 30 (1997) 647-649
24. Lewis D.P., Van Dyke D.C., Willhite L.A., Stumbo P.J., and Berg M.J. Phenytoin-folic acid interaction. Ann Pharmacother 29 (1995) 726-735
25. Billings R.E. Decreased hepatic 5,10-methylenetetrahydrofolate reductase activity in mice after chronic phenytoin treatment. Mol Pharmacol 25 (1984) 459-466
26. Lambie D., and Johnson R. Drugs and folate metabolism. Drugs 30 (1985) 145-155
27. Froscher W., Maier V., Laage M., Wolfersdorf M., Straub R., Rothmeier J., et al. Folate deficiency, anticonvulsant drugs and psychiatric morbidity. Clin Neuropharmacol 18 (1995) 165-182
28. Yoo J.H., and Hong S.B. A common mutation in the methylenetetrahydrofolate reductase gene is a determinant of hyperhomocysteinemia in epileptic patients receiving anticonvulsants. Metabolism 48 (1999) 1047-1051
29. McClean R.R., Jacques P.F., Selhub J., Tucker K.L., Samelson E.J., Broe K.E., et al. Homocysteine as a predictive factor for hip fractures in older persons. N Engl J Med 350 (2004) 2042-2049
30. Van Meurs J.B.J., Dhonukshe-Rutten R.A.M., Puijm S.M.F., van der Klift M., de Jonge R., Lindemans J., et al. Homocysteine levels and the risk of osteoporotic fractures. N Engl J Med 350 (2004) 2033-2041
31. Goldbahar J., Hamidi A., Aminzadeh A.A., and Omrani G.R. Association of plasma folate, plasma homocysteine, but not methylenetetrahydrofolate reductase C667T polymorphism, with bone mineral density in postmenopausal Iranian women: a cross-sectional study. Bone 35 (2004) 760-765
32. Sato Y., Iwamoto J., Kanoko T., and Satoh K. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med 118 (2005) 1250-1255
33. Cagnacci A., Baldassari F., Rivolta G., Arangino S., and Volpe A. Relation of homocysteine, folate, and Vitamin B12 to bone mineral density of postmenopausal women. Bone 33 (2003) 956-959
34. Morris M.S., Jacques P.F., and Selhub J. Relation between homocysteine and B-Vitamin status indicators and bone mineral density in older Americans. Bone 37 (2005) 234-242
35. Gjesdal C.G., Vollset S.E., Ueland P.M., Refsum H., Drevon C.A., Gjessing H.K., et al. Plasma total homocysteine level and bone mineral density: the Hordaland Homocysteine Study. Arch Intern Med 166 (2006) 88-94
36. Dhonukshe-Rutten R.A., van Dusseldorp M., Schneede J., de Groot L.C., and van Staveren W.A. Low bone mineral density and bone mineral content are associated with low cobalamin status in adolescents. Eur J Nutr 44 (2004) 341-347
37. Lubec B., Fang-Kircher S., Lubes T., Blom H.J., and Boers G.H.J. Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim Biophys Acta 1315 (1996) 159-162
38. Grieco A. Homocystinuria: pathogenetic mechanisms. Am J Med Sci 273 (1977) 120-132
39. Miyao M., Morita H., Hosoi T., Kurihara H., Inoue S., Hoshino S., et al. Association of methylenetetrahydrofolate reductase (MTHFR) polymorphism with bone mineral density in postmenopausal Japanese women. Calcif Tissue Int 66 (2000) 190-194
40. McCarty M. Supplemental arginine and high-dose folate may promote bone health by supporting the activity of endothelial-type nitric oxide synthase in bone. Med Hypotheses 64 (2005) 1030-1033
41. Sato Y., Honda Y., Iwamoto J., Kanoko T., and Satoh K. Effect of folate and mecobalamin on hip fractures in patients with stroke. J Am Med Assoc 293 (2005) 1082-1088
42. Freed W. Selective inhibition of homocysteine-induced seizures by glutamic acid diethyl ester and other glutamate esters. Epilepsia 26 (1985) 30-36
43. Freed W., Taylor S., Luchins D., Wyatt R., and Gillin J. Production of convulsions in mice by the combination of methionine and homocysteine. Psychopharmacology 69 (1980) 275-280
44. Folbergrova J. Anticonvulsant action of both NMDA and non-NMDA receptor antagonists against seizures induced by homocysteine in immature rats. Exp Neurol 145 (1997) 442-450
45. Pfeiffer C.M., Caudill S.P., Gunter E.W., Osterloh J., and Sampson E.J. Biochemical indicators of B Vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999-2000. Am J Clin Nutr 82 (2005) 442-450
46. Department of Health and Human Services. National Institutes of Health. National Heart, Lung and Blood Institute, Obesity Education Initiative. [cited 2006 February 22]. Available from: URL: http://nhlbisupport.com/bmi.
47. Fokkema M.R., Gilissen M.F., Van Doormaal J.J., Volmer M., Kema I.P., and Muskiet F.A. Fasting vs nonfasting plasma homocysteine concentrations for diagnosis of hyperhomocysteinemia. Clin Chem 49 (2003) 818-821
48. Thirup P., and Ekelund S. Day-to-day, postprandial, and orthostatic variation of total plasma homocysteine. Clin Chem 45 (1999) 1280-1283
49. Pack A.M. The association between antiepileptic drugs and bone disease. Epilepsy Curr 3 (2003) 91-95
50. Gloth F.M. Practical approach to bone health in epilepsy: how to prevent, evaluate and treat. Epilepsy Netw News 11 (2005) 1-4
51. Zoccali C. Traditional and emerging cardiovascular and renal risk factors: an epidemiological perspective. Kidney Int 70 (2006) 26-33
52. Ono H., Sakamoto A., Eguchi T., Fujita N., Nomura S., Ueda H., et al. Plasma total homocysteine concentrations in epileptic patients taking anticonvulsants. Metabolism 46 (1997) 959-962
53. Robinson K., Mayer E.L., Miller D.P., Green R., van Lente F., Gupta A., et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 92 (1995) 2825-2830
54. Felson D.T., Kiel D.P., Anderson J.J., and Kannel W.B. Alcohol consumption and hip fractures. The Framingham Study. Am J Epidemiol 128 (1998) 1102-1110
55. Kanis J.A., Johansson H., Johnell O., Oden A., DeLaet C., Eisman J.A., et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 16 (2005) 737-742
56. Naves Diaz M., O'Neill T.W., and Silman A.J. The influence of alcohol consumption and the risk of vertebral deformity. European Vetebral Osteoporosis Study Group. Osteoporos Int 7 (1997) 65-71
57. Sabatier J.P., Guaydier-Souquieres G., Laroche D., Benmalek A., Fournier L., Guillon-Metz F., et al. Bone mineral acquisition during adolescence and early adulthood: a study in 574 healthy females 10-24 years of age. Osteoporos Int 6 (1996) 141-148
58. Heinonen A., Kannus P., Sievane H., Oja P., Pasanen M., Rinne M., et al. Randomized controlled trial of effect of high-impact exercise on selected risk factors for osteoporotic fractures. Lancet 348 (1996) 1343-1347
59. Schettler A.E., and Gustafson E.M. Osteoporosis prevention starts in adolescence. J Am Acad Nurse Pract 16 (2004) 274-282
60. Utiger R.D. The need for more Vitamin D. N Engl J Med 338 (1998) 828-829
61. Hollis B.W., and Wagner C.L. Normal serum Vitamin D levels. N Engl J Med 352 (2005) 515
62. Marci C.D., Viechnicki M.B., and Greenspan S.L. Bone mineral densitometry substantially influences health-related behaviors of postmenopausal women. Calcif Tissue Int 66 (2000) 113-118